Julie Jordan
Keine laufenden Positionen mehr
Vermögen: 11 748 $ am 30.04.2024
Profil
Julie Jordan is currently the Chief Medical Officer at Neurogene, Inc. Prior to her current position, she worked as an Executive Director of Clinical Development at Avanir Pharmaceuticals, Inc. and as a Senior Director of Clinical Development at Cerevel Therapeutics, Inc. She also served as the Senior VP and Head of Clinical Development and Operations at Homology Medicines, Inc. from 2022 to 2023.
Dr. Jordan received her doctorate degree from Harvard Medical School and her undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,00% | 03.08.2023 | 416 ( 0,00% ) | 11 748 $ | 30.04.2024 |
Aktive Positionen von Julie Jordan
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Julie Jordan
| Unternehmen | Position | Ende |
|---|---|---|
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Corporate Officer/Principal | - |
| AVANIR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
| Q32 BIO INC. | Geschäftsführer | 09.03.2023 |
Ausbildung von Julie Jordan
| Harvard College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
